Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events

British Journal of Clinical Pharmacology

Volumn 65, Issue 5, 2008, Pages 723-732

  Boersma, Cornelis ^a   Postma, Maarten J ^a   Visser, Sipke T ^a   Atthobari, Jarir ^a   De Jong, Paul E ^b   De Jong Van Den Berg, Lolkje T W ^a   Gansevoort, Ron T ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Albuminuria; Blood pressure; Cardiovascular diseases; Prevention

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; HEART PROTECTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN URINE LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 42249092076     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03097.x     Document Type: Article

References (38)

1. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 21 : 1011 53.
2. Withworth JA World Health Organization International Society of Hypertension Writing Group. 2003 World Health Organization (WHO) /International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003 21 : 1983 92.
3. Cifkova R, Erdine S, Fagard R, Farsang C, Heagerty AM, Kiowski W, Kjeldsen S, Lüscher T, Mallion JM, Mancia G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM, van Zwieten P, Waeber B, Williams B, Zanchetti A ESH/ESC Hypertension Guidelines Committee. Practice guidelines for primary care physicians: ESH/ESC hypertension guidelines. J Hypertens 2003 22 : 1779 86.
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Roccella EJ National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 289 : 2560 72.
5. Bakris G. Inclusion of albuminuria in hypertension and heart guidelines. Kidney Int Suppl 2004 92 : S124 5.
6. Pedrinelli R, Dell'Omo G, Di Bello V, Pontremoli R, Mariani M. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens 2002 16 : 79 89.
7. Terpstra WF, May JF, Smit AJ, de Graeff PA, Crijns HJ. Microalbuminuria is related to marked end-organ damage in previously untreated, elderly, hypertensive patients. Blood Press 2002 11 : 84 90.
8. Verhave JC, Hillege HL, Burgerhof JGM, Navis G, de Zeeuw D, de Jong PE Prevend Study Group. Cardiovascular risk factors are differently associated with urinary albumin excretion in men and women. J Am Soc Nephrol 2003 14 : 1330 5.
9. Tsioufis C, Dimitriades K, Antoniades D, Stefanadis C, Kallikazaros I. Inter-relationship of micro-albuminuria with the other surrogates of atherosclerotic cardiovascular disease in hypertensive subjects. Am J Hypertens 2004 17 : 470 6.
10. Palatini P. Microalbuminuria in hypertension. Curr Hypertens Rep 2003 5 : 208 14.
11. Campese VM, Bianchi S, Bigazzi R. Association between hyperlipidemia and microalbuminuria in essential hypertension. Kidney Int Suppl 1999 56 : S10 3.
12. Pontremoli R, Sofia A, Ravera M, Nicolella C, Viazzi F, Tirotta A, Ruello N, Tomolillo C, Castello C, Grillo G, Sacchi G, Deferrari G. Prevalence and clinical correlates of microalbuminuria in essential hypertension. The MAGIC Study. Hypertension 1997 30 : 1135 43.
13. Hillege HL, Janssen WMT, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, van Gilst WH, de Zeeuw D, de Jong PE Prevend Study Group. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001 249 : 519 26.
14. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ 1996 313 : 779 84.
15. Anavekar NS, Gans DJ, Berl T, Rohde RD, Cooper W, Bhaumik A, Hunsicker LG, Rouleau JL, Lewis JB, Rosendorff C, Porush JG, Drury PL, Esmatjes E, Raz I, Vanhille P, Locatelli F, Goldhaber S, Lewis EJ, Pfeffer MA. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int 2004 66 (Suppl. 92 S50 5.
16. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE, Prevention of Renal and Vascular Endstage Disease (Prevend) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in the general population. Circulation 2002 106 : 1777 82.
17. Jager A, Kostens PJ, Ruhé HG, Heine RJ, Nijpels G, Dekker JM, Bouter JM, Stehouwer CD. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five year follow-up of the Hoorn Study. Arterioscl Thromb Vasc Biol 1999 19 : 617 24.
18. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S, Hope Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001 286 : 421 6.
19. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, Wareham NJ. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study. Am J Epidemiol 2004 159 : 284 93.
20. de Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: public health perspectives. J Am Soc Nephrol 2006 17 : 2120 6.
21. Basi S, Lewis JB. Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am J Kidney Dis 2006 47 : 927 46.
22. Asselbergs FW, Diercks GFH, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH, Prevention of Renal and Vascular Endstage Disease Intervention Trial (Prevend IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004 110 : 2809 16.
23. Pinto-Sietsma SJ, Janssen WM, Hillege HL, Navis G, de Zeeuw D, de Jong PE. Urinary albumin excretion is associated with renal function abnormalities in a nondiabetic population. J Am Soc Nephrol 2000 11 : 1882 8.
24. Pharmacy-dispensing database of IADB.nl. Available at http://www.iadb.nl (last accessed 20 July 2007)
25. Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT, Prevend Study Group. Pharmacy data in epidemiological studies: an easy to obtain reliable tool. Pharmcoepidemiol Drug Saf 2002 11 : 379 84.
26. WHO Collaborating Centre for Drugs Statistics Methodology. ATC/DDD Index 2005. Available at http://www.whocc.no/atcddd (last accessed: 8 August 2007)
27. Prismant. National LHR information [in Dutch]. Available at http://www.prismant.nl [data specifically requested] (Last accessed: 8 June 2007)
28. http://www.cbs.nl/nl-NL/default.htm
29. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on propensity score. J Am Stat Assoc 1984 79 : 516 24.
30. Cook EF, Goldman L. Asymmetric stratification. An outline for an efficient method for controlling confounding in cohort studies. Am J Epidemiol 1988 127 : 626 39.
31. Collins R, Peto R, Macmahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990 335 : 827 38.
32. Neal B, Macmahon S, Chapman N Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000 356 : 1955 64.
33. Yusuf S, Sleight G, Pogue J, Bosch J, Davies R, Dagenais G the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000 342 : 145 53.
34. Solomon SD, Rice MM, Jablonski KA, Jose P, Domanski M, Sabatine M, Gersh BJ, Rouleau J, Pfeffer MA, Braunwald E Prevention of Events with ACE inhibition (PEACE) Investigators. Renal function and effectiveness of angiotensin- converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the prevention of events with ACE inhibition (PEACE) trial. Circulation 2006 114 : 26 31.
35. Reddan DN, Szczech L, Bhapkar MV, Moliterno DJ, Califf RM, Ohman EM, Berger PB, Hochman JS, van der Werf F, Harrington RA, Newby LK. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial Transplant 2005 20 : 2105 12.
36. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989 32 : 219 26.
37. Verhave JC, Hillege HL, Burgerhof JG, Gansevoort RT, de Zeeuw D, de Jong PE Prevend Study Group. The association between atherosclerotic risk factors and renal function in the general population. Kidney Int 2005 67 : 1967 73.
38. Vandenbroucke JP. Benefits and harms of drug treatments. Observational studies and randomised trials should learn from each other. BMJ 2004 329 : 2 3.